First patient dosed in risperidone clinical trial for schizophrenia, bipolar disorder

A biopharmaceutical company announced it has dosed the first patient in a clinical trial of a long-acting oral treatment for schizophrenia, schizoaffective disorder and bipolar I disorder, according to a company press release.

Related Keywords

Shenaz Bagha ,Richard Scranton , ,Lyndra Therapeutics ,Adobe Stock ,